Key facts
- Sanofi now expects sales to grow by a low-teens percentage in 2026.
- The company previously forecast 10% sales growth.
- Sanofi expects business operating income per share to grow by a mid-teens percentage.
- The company is considering deals larger than its historical €2 billion to €5 billion range.
- Sanofi reported third-quarter business operating income of €5.43 billion.
French drugmaker Sanofi on Friday raised its full-year sales growth expectations to a low-teens percentage, up from a previous forecast of 10%, citing strong demand for its blockbuster asthma drug Dupixent. The company also anticipates business operating income per share to grow by a mid-teens percentage, a revision from its earlier expectation that operating income would grow slightly faster than sales. Sanofi's new CEO, Belen Garijo, is leading a strategic review and has indicated a willingness to pursue larger mergers and acquisitions than the company's historical €2 billion to €5 billion range. CFO François Roger stated that Sanofi is considering deals in areas of strength such as rare diseases, vaccines, and immunology, and potentially "white spaces or moonshots with unmet medical needs." Analysts estimate the company has approximately €20 billion in deal-making firepower. Sanofi reported third-quarter business operating income of €5.43 billion, surpassing market expectations of €4.32 billion.